Biotech Minicaps to AI Agents: Silo Pharma’s Qwikagents Deal Aims at a Multi‑Billion‑Dollar Market

Silo Pharma (NASDAQ: SILO) is jumping into the AI boom, acquiring the Qwikagents.ai platform and launching a dedicated AI subsidiary to target the fast‑growing “AI agent” infrastructure market alongside its existing biotech and crypto‑treasury businesses.

Deal snapshot

Silo Pharma has purchased the assets of Qwikagents.ai, a managed platform designed to deploy autonomous AI agents that can handle tasks like research, content generation, scheduling, and workflow automation for businesses and individuals. The company will operate Qwikagents through a new AI‑focused subsidiary, positioning it as a separate line of business next to Silo’s psychedelic‑adjacent PTSD program and digital asset treasury.

Market opportunity

Management cites third‑party estimates that peg the AI‑agent market at roughly 47–53 billion dollars by 2030, implying about 6x growth in four years with annual expansion rates between 43% and 50%. The idea is that AI agents will become a core layer of AI infrastructure—routing work across multiple large models and automating repetitive, knowledge‑heavy tasks—creating room for platforms like Qwikagents that offer smart routing, cost optimization, and managed deployment.

Strategic angle for SILO

For Silo Pharma, the move is framed as diversification into a second high‑growth vertical rather than a pivot away from biotech. The company is still planning to submit an IND for its SPC‑15 program in PTSD and advance it into Phase 1 after clearance, while the AI arm is expected to open up a new potential revenue stream that’s less dependent on binary clinical milestones. With a micro‑cap market value in the single‑digit millions, even modest traction in a multi‑billion‑dollar AI‑agent market could be material to the SILO story—though it also adds execution risk as management splits focus between drug development, AI infrastructure, and crypto treasury management.